ABCL-1224: Updated Results From EPCORE NHL-6: Phase 2 Study of Subcutaneous Epcoritamab as Outpatient Treatment for 2L+ Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
Rakhee Vaidya(Atrium Health Wake Forest Baptist), David Andorsky(Sheba Medical Center), Kristin Conte(AbbVie (United States)), Christian Winther Eskelund(Rigshospitalet), Sundaram Suchitra(Icahn School of Medicine at Mount Sinai), Kojo Osei-Bonsu(AbbVie (United States)), Farrukh T. Awan(The University of Texas Southwestern Medical Center), Noridza Rivera-Rodríguez, John Hrom(Hattiesburg Clinic), Yang Bai(AbbVie (United States)), Neha Dixit(Nektar Therapeutics (United States)), Jeff P. Sharman(Willamette Valley Cancer Institute and Research Center), Ralph V. Boccia(Center for Cancer and Blood Disorders), Eric H. Lee(Compassionate Cancer Care)
Cited by 1
Related Papers
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
|Journal of Clinical Oncology|2012|1.1k
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|890
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
|Breast Cancer Research and Treatment|2017|761